

Bone Day

20 June 2025

<u>Pathophysiological aspects underlining the rebound phenomenon after denosumab</u> discontinuation

A/Prof Michelle McDonald

Group Leader, Bone Microenvironment Group, University of Sydney

Session 2

Moderator: Lara Graves

<u>The road ahead: exploring the unknowns of burosumab therapy in X-linked hypophosphataemia</u>

Dr Jessica Sandy

Paediatric Endocrinologist, The Children's Hospital at Westmead

PhD candidate, University of Sydney

<u>Levelling the playing field – outcomes beyond height in children with achondroplasia</u> <u>after 12 months' treatment with Voxzogo</u>

Dr Penny Ireland

Physiotherapist & Team Leader, Qld Paediatric Rehabilitation Service

School of Health and Rehabilitation Sciences, University of Queensland

Case Presentations

Moderator: Phoebe Stewart

Osteonecrosis of the jaw in a paediatric patient on bisphosphonates

Dr Priya Chhiba

Clinical Fellow, Royal Children's Hospital, Melbourne

Concurrent use of burosumab and calcitriol in XLH

Dr Karissa Ludwig (presented by Dr Clinton Roddick)

Paediatric Endocrinologist, Qld Children's Hospital & West Moreton Health

<u>Update on patient with complications including metaphyseal fracture after prolonged</u> denosumab treatment

Dr Karissa Ludwig (presented by Dr Clinton Roddick)

Paediatric Endocrinologist, Qld Children's Hospital & West Moreton Health